# Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma (2024)

## TL;DR

This paper presents a Chinese expert consensus on diagnosing and treating high-risk multiple myeloma to improve patient outcomes.

## Contribution

The paper introduces a unified consensus on defining and managing high-risk multiple myeloma in China.

## Key findings

- HRMM is defined as myeloma with a survival of less than 2-3 years under current treatments.
- Experts propose a risk stratification system and treatment strategies for HRMM patients.
- The consensus aims to standardize HRMM diagnosis and treatment in China.

## Abstract

高危多发性骨髓瘤（High risk multiple myeloma，HRMM）是指在当前规范诊疗下，总生存期不足2～3年的骨髓瘤患者。结合多种静态和动态预后因素进行危险度分层，早期识别HRMM患者，并采用个体化风险分层治疗策略，有望显著改善HRMM患者不良生存结局。尽管近年来，国内对HRMM的临床价值已达成共识，但在HRMM的定义、高危因素、危险度分层和治疗等方面仍存在混乱和不明确之处，亟需规范。为提高中国医师对HRMM的诊治水平，中国抗癌协会血液肿瘤专业委员会和中国临床肿瘤学会多发性骨髓瘤专家委员会组织相关专家制定了本共识。该共识旨在明确HRMM的定义、高危因素和危险度分层体系，提供HRMM的治疗推荐，从而提高中国HRMM患者的生存质量和预后。